CN1695665A - Medication for treating gout - Google Patents
Medication for treating gout Download PDFInfo
- Publication number
- CN1695665A CN1695665A CN 200410081341 CN200410081341A CN1695665A CN 1695665 A CN1695665 A CN 1695665A CN 200410081341 CN200410081341 CN 200410081341 CN 200410081341 A CN200410081341 A CN 200410081341A CN 1695665 A CN1695665 A CN 1695665A
- Authority
- CN
- China
- Prior art keywords
- medicine
- present
- gout
- chinese medicine
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 201000005569 Gout Diseases 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title description 19
- 239000007787 solid Substances 0.000 claims abstract description 3
- 239000008589 Cortex Fraxini Substances 0.000 claims description 10
- 241000903946 Clematidis Species 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 6
- 239000008297 liquid dosage form Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 3
- 206010018634 Gouty Arthritis Diseases 0.000 abstract description 2
- 230000001154 acute effect Effects 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000218158 Clematis Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 231100000862 numbness Toxicity 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CRSFLLTWRCYNNX-UHFFFAOYSA-N Fraxin Natural products OC=1C(OC)=CC=2C=CC(=O)OC=2C=1OC1OC(CO)C(O)C(O)C1O CRSFLLTWRCYNNX-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- CRSFLLTWRCYNNX-QBNNUVSCSA-N fraxin Chemical compound OC=1C(OC)=CC=2C=CC(=O)OC=2C=1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CRSFLLTWRCYNNX-QBNNUVSCSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 206010023215 Joint effusion Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 201000001819 hydrarthrosis Diseases 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating acute or chronic gout, tophus, gouty arthritis, and hyperuricemia is prepared from ash bark, clematis root, Chinese angelica root and Chuan-xiong rhizome through conventional process to obtain solid or liquid.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of gout, relating to a kind of particularly is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.
Background technology
Chinese medicine thinks that the pathogenesis of goat mainly is a congenital defect, and healthy energy is lost empty, and passages through which vital energy circulates loses supports; Or turbid damp is drained slow lacking, the stagnant passages through which vital energy circulates of stream; Or spleen fortune mistake department, the turbid sluggish joint of expectorant; Or being invaded by exogenous pathogen, evil numbness passages through which vital energy circulates, QI-blood circulation is not smooth.The result all causes joint, muscles and bones, myalgia, swelling, red heat, numbness, is weighing, joint stuffiness and form primary disease.Obstinate disease is blood-vessel obstructive then, body fluid cohesion, and ecchymosis, tuberosity around phlegm-turbidity and blood stasis blood impatency meridians and arthroncus, deformity, stiff, the joint, and interior damage internal organs can concurrent Zang-Fu syndromes, and then the state of an illness is complicated and serious.Aspect method of treatment, dissimilar according to gout are adopted heat clearing away collateral dredging, expelling wind and removing dampness respectively, or expelling wind and cold, eliminating dampness and dredging channels, or blood circulation promoting and blood stasis dispelling, eleminating phlegm and freeing channels, or benefiting vital QI and blood, adjusting and reinforcing liver and kidney, expelling wind and dampness, activating collaterals to relieve pain etc. have been obtained better curative effect clinically.
Gout (gout) is that purine metabolic disturbance and/or urate excretion reduce caused one group of disease.Its clinical characters is acute arthritis, tophus deposition, tophus chronic arthritis and the joint deformity that hyperuricemia (hyperuricimia), characteristic are shown effect repeatedly, often involves kidney and causes that chronic interstitial nephritis and uric acid renal calculus form.Primary disease is many with the male, betides person between twenty and fifty well; After the women is mainly seen in menopause.The goat philtrum, trader, cadre are more than workman, peasant, and the outbreak of winter-spring season gout is more.Along with people increase the consumption proportion of food such as drinks, meat, the sickness rate of gout has the trend that rises year by year, reaches about 1% at present, but up to the present, does not still have the medicine of ideal treatment gout.The western medicine gout at short notice truly have certain curative effect, but serious toxic and side effects is arranged; And that common tcm prescription is formed the most delicious number at medical material is more and change greatlyyer, is difficult to use in a wider context.Though it is many to belong to the rheumatismal Chinese patent medicine of the traditional Chinese medical science at present, but the special for treating gout seldom, all introduced the prescription for the treatment of gout separately respectively as Chinese patent 01106831,98108536,98121618,99126277, but the Chinese medicine raw material types of these prescriptions is more.
Summary of the invention
The present invention is to the original explanation of gout pathogeny and the rule of treatment and a kind of medicine for the treatment of gout of making contains Cortex Fraxini, Radix Clematidis, Radix Angelicae Sinensis and Rhizoma Chuanxiong in the medicine of the present invention according to China's Chinese medicine and pharmacy.Cortex Fraxini nature and flavor bitter cold among its side can removing damp-heat, can exempt from the numbness pain relieving again.Modern pharmacological research proves, the contained aseculin of Cortex Fraxini, aesculetin, fraxin etc. have tangible antiinflammatory action to swelling of the feet due to artificial; Aesculetin also has analgesic activity; Fraxin has diuresis; Aseculin can increase urate excretion.The hot temperature of loosing of Radix Clematidis is logical, can expelling wind and removing dampness, again can removing obstruction in the collateral to relieve pain, thus all rheumatic arthralgia, the contracture of muscle arteries and veins, it is unfavorable that the joint song is stretched, and all can use.The sweet suffering of Radix Angelicae Sinensis is gentle, can enrich blood, again can promoting the circulation of blood, and good analgesic effect is arranged, the blood deficiency stasis there is the arthralgia of wind-damp numbness, and can work in coordination with Cortex Fraxini, Radix Clematidis is obtained better curative effect.Rhizoma Chuanxiong also is the hot logical product of temperature that loose, and is the gas medicine in the blood, can blood-activating and qi-promoting, and the bypass channels again can wind-expelling pain-stopping, and the pain of QI and blood stasis and wind-damp numbness is very imitated.Radix Angelicae Sinensis, Rhizoma Chuanxiong two medicines share, but both circulation of qi promoting promoting blood circulation and stopping pain, again can nourishing blood to expel wind.Four medicines share, and coordinate mutually, can encourage its elimination to main disease to be treated and etiology and pathogenesis, thereby produce the result of unexpected treatment gout.
The raw material of Chinese medicine consumption of drug regimen of the present invention through the inventor grope in a large number sum up, the research checking draws repeatedly, the consumption of each component all has curative effect preferably in the scope of following weight part ratio example:
225～375 parts of 225～375 parts of Radix Angelicae Sinensis of 450～750 parts of Radix Clematidis of Cortex Fraxini
225～375 parts of Rhizoma Chuanxiongs
The part by weight of each tcm components raw material that medicine of the present invention can adopt especially is:
300 parts of 300 parts of Rhizoma Chuanxiongs of 300 parts of Radix Angelicae Sinensis of 600 parts of Radix Clematidis of Cortex Fraxini
The present invention can make different solid and liquid absorption member such as granule, capsule, oral liquid with the conventional formulation method of general Chinese patent medicine, wherein when raw material of Chinese medicine being decocted extraction, should collect volatile oil simultaneously, and before making preparation, add in the preparation.
Medicine of the present invention is a raw material with pure Chinese herbal medicine, formulated through science, have expelling wind and removing dampness and arrange function turbid, promoting blood circulation, dredging meridian and relieving pain, effects such as antiinflammatory, analgesia, inhibition capillary permeability increase, blood circulation promoting and blood stasis dispelling, diuresis are arranged, be used for the treatment of diseases such as acute and chronic gout, hyperuricemia, gouty arthritis, tophus.
The specific embodiment
Further set forth the beneficial effect of medicine of the present invention below by the specific embodiment, these specific embodiment have comprised the toxicity test and the results of pharmacodynamic test of medicine of the present invention.
Toxicity test:
Give mouse gavaging and disposable celiac injection carrying out acute toxicity test with the extract of medicine of the present invention as test specimen.The result shows: the maximum tolerated dose of mouse gavaging medicine of the present invention is that 47.04g/kg/24h (is equivalent to 235.2g crude drug in whole/kg/24h), is 156.8 times of 60kg body weight adult clinical oral administration day dosage; The LD of mice disposable celiac injection
50(be equivalent to 13.1g crude drug in whole/kg), the 95% credible 2.10～3.28g/kg that is limited to (is equivalent to 10.50g～16.40g crude drug in whole/kg) for 2.62g/kg.Long term toxicity test shows, rat gavages the extract 2,5,12g/kg (be equivalent to clinical amount 10,25,60 times) of medicine of the present invention every day, 8 week back hematologys, blood biochemical are learned relatively all no significant differences of index, organ coefficient and matched group, and pathological examination results does not also see that drug-induced pathologic changes.After 2 weeks of drug withdrawal, every index of each administration group and matched group compare, and all no significant difference points out this medicine not have obvious retardance toxicity.Illustrate that it also is safe that medicine of the present invention is taken for a long time.
Pharmacodynamic test of active extract:
Be that tester is investigated medicine of the present invention uric acid sodium (MSU) is induced the influence of rat paw edema with the etidocine tablet, with laboratory sample by 2.4,1.2,0.6g/kg (be equivalent to 12,6, high, medium and low three dosed administrations of 3g crude drug/kg).The result show medicine height of the present invention, middle dosage (12, the rat paw edema of 6g crude drug/kg) MSU is caused all has obvious suppression effect (P＜0.01 or P＜0.05).
With the etidocine tablet is that tester is investigated medicine of the present invention is induced the rabbit acute arthritis to MSU influence, the result shows that medicine height of the present invention, middle dosage (consumption is the same) all can obviously reduce the numeration of leukocyte (P＜0.01) of MSU in the hydrarthrosis in rabbit joint, obviously alleviates the inflammatory reaction degree of synovial tissue of joint and synovial cell's degeneration, necrosis etc. (P＜0.01 or P＜0.05).
Can be tester with hydrogenation and investigate the influence of medicine of the present invention the mouse peritoneal capillary permeability, with test specimen by 3.6,1.8,0.9g/kg (be equivalent to 18,9, high, medium and low three dosed administrations of 4.5g crude drug/kg).The result show medicine height of the present invention, middle dosage (18,9g crude drug/kg) all can obviously suppress the mouse peritoneal capillary permeability that acetic acid causes and increase (P＜0.01).
With the pethidine hydrochloride is that tester is investigated the analgesic activity of medicine of the present invention to the mice hot plate method, and the result shows the effect (P＜0.01 or P＜0.05) that all had the inhibition thermostimulation to cause mice pain in 60 minutes, 120 minutes, 180 minutes behind medicine of medicine height of the present invention, middle dosage (consumption is the same).
With indometacin and pethidine hydrochloride is that tester is investigated medicine of the present invention glacial acetic acid is caused the analgesic activity (writhing method) of mice inflammatory pain, and the result shows that the high, medium and low dosage of medicine of the present invention (consumption is the same) all has obvious inhibitory action (P＜0.01) to the pain reaction (writhing response) that mouse peritoneal injection acetic acid causes.
Is the diuresis that tester is investigated medicine of the present invention with the hydrochlorothiazide tablet, with test drug by 2.4,1.2,0.6g/kg (be equivalent to 12,6, high, medium and low three dosed administrations of 3g crude drug/kg).The result show medicine height of the present invention, middle dosage (12,6g crude drug/kg) had tangible diuresis (P＜0.01 or P＜0.05) in 1～4 hour after administration, and high dose group is to Na in 4 hours urine
+, K
+And Cl
-The significant decorporation effect of letting out (P＜0.01) is arranged.
Is that tester is investigated the influence of medicine of the present invention to blood stasis model rat blood rheological characteristic with the compound Salviae Miltiorrhizae, with test drug by be equivalent to 18.0,9.0, high, medium and low three dosed administrations of 4.5g crude drug/kg.Test shows, medicine high dose of the present invention (18.0g crude drug/kg) can reduce blood stasis model rat 5S
-1The whole blood viscosity of shear rate and plasma viscosity value (P＜0.01 or P＜0.05).
Come further to set forth medicine of the present invention by the following examples.
Embodiment 1: the granule preparation of medicine of the present invention
Get the raw material of Chinese medicine of following weight: Cortex Fraxini 650g, Radix Clematidis 325g, Radix Angelicae Sinensis 320g, Rhizoma Chuanxiong 330g, soak 1～1.5 hour after, the decocting that adds 7～12 times of amounts respectively boils 3 times, time is respectively 40～100 minutes (collecting volatile oil when decocting for the first time simultaneously), merge decoction liquor, filter, be concentrated into relative density 1.08～1.12; The spray-dried extract powder of making is crossed 80 mesh sieves, adds an amount of mixing of dextrin, adds sweet generation sugar 5g mixing again; Add an amount of 92% ethanol and make soft material, cross 12 mesh sieves and granulate, 40～60 ℃ of dryings, cross 12 mesh sieve granulate: spray into volatile oil ethanol liquid, airtight moistening 65～70 minutes is packed as 100 bags, every bag of 5g, promptly.
Embodiment 2: the oral liquid preparation of medicine of the present invention
Get the raw material of Chinese medicine of following weight: Cortex Fraxini 625g, Radix Clematidis 320g, Radix Angelicae Sinensis 315g, Rhizoma Chuanxiong 310g, soak 1～1.5 hour after, the decocting that adds 10,8 times respectively boils 2 times, time is respectively 90,60 minutes (collecting volatile oil when decocting for the first time simultaneously), merge decoction liquor, filter, be concentrated into relative density 1.05～1.20, adding ethanol makes and contains alcohol amount and reach 70%～80%, left standstill 24 hours, and filtered, centrifugal behind the decompression filtrate recycling ethanol; Get volatile oil that supernatant add to collect and polyoxyethylene sorbitan monoleate 10g, cyclamate 0.5g, sorbic acid 2g, mixing adds water to 1000ml, filter, and fill, sterilization, promptly.
Claims (4)
1. Chinese medicine preparation for the treatment of gout is characterized in that it contains following medicine (by ratio of weight and the number of copies):
Cortex Fraxini 450～750 Radix Clematidis 225～375 Radix Angelicae Sinensis 225～375
Rhizoma Chuanxiong 225～375
2. according to claims 1 described Chinese medicine preparation, it is characterized in that the preferred disposition ratio is:
Cortex Fraxini 600 Radix Clematidis 300 Radix Angelicae Sinensis 300 Rhizoma Chuanxiongs 300
3. according to claim 1,2 described Chinese medicine preparation, it is characterized in that said preparation is said solid and a liquid dosage form on any pharmaceutics.
4. when decocting claim 1,2 described raw material of Chinese medicine, collect their volatile oil and be used for preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100813412A CN100457143C (en) | 2004-11-29 | 2004-11-29 | Medication for treating gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100813412A CN100457143C (en) | 2004-11-29 | 2004-11-29 | Medication for treating gout |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1695665A true CN1695665A (en) | 2005-11-16 |
| CN100457143C CN100457143C (en) | 2009-02-04 |
Family
ID=35348654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100813412A Active - Reinstated CN100457143C (en) | 2004-11-29 | 2004-11-29 | Medication for treating gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100457143C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100368000C (en) * | 2006-02-17 | 2008-02-13 | 朱良春 | Compound fleece-flower root granula for gout |
| CN1943651B (en) * | 2006-10-20 | 2010-09-01 | 荣凯 | A medicinal composition for treating gout |
| CN101732386B (en) * | 2008-11-04 | 2012-03-21 | 江苏康缘药业股份有限公司 | Medicinal composition for treating gout, preparation method thereof and purposes thereof |
| CN102105153B (en) * | 2008-05-22 | 2014-03-05 | 百时美施贵宝公司 | Method for treating hyperuricemia employing SGLT2 inhibitor and composition containing same |
| CN107617017A (en) * | 2017-10-27 | 2018-01-23 | 沈瑞金 | A kind of Chinese medicine for treating tophus |
| CN111375002A (en) * | 2020-03-20 | 2020-07-07 | 成都华西天然药物有限公司 | Pharmaceutical composition for treating hyperuricemia and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1413664A (en) * | 2002-06-05 | 2003-04-30 | 徐冬雁 | Chinese medicine for treating gout |
-
2004
- 2004-11-29 CN CNB2004100813412A patent/CN100457143C/en active Active - Reinstated
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100368000C (en) * | 2006-02-17 | 2008-02-13 | 朱良春 | Compound fleece-flower root granula for gout |
| CN1943651B (en) * | 2006-10-20 | 2010-09-01 | 荣凯 | A medicinal composition for treating gout |
| CN102105153B (en) * | 2008-05-22 | 2014-03-05 | 百时美施贵宝公司 | Method for treating hyperuricemia employing SGLT2 inhibitor and composition containing same |
| CN101732386B (en) * | 2008-11-04 | 2012-03-21 | 江苏康缘药业股份有限公司 | Medicinal composition for treating gout, preparation method thereof and purposes thereof |
| CN107617017A (en) * | 2017-10-27 | 2018-01-23 | 沈瑞金 | A kind of Chinese medicine for treating tophus |
| CN111375002A (en) * | 2020-03-20 | 2020-07-07 | 成都华西天然药物有限公司 | Pharmaceutical composition for treating hyperuricemia and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100457143C (en) | 2009-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003203783A1 (en) | Herbal pharmaceutical composition for treatment of HIV/AIDS patients | |
| CN102078543B (en) | Traditional Chinese medicine preparation for treating gout and preparation method thereof | |
| CN103705687B (en) | A kind ofly prevent and treat Chinese medicine composition of early stage chronic kidney hypofunction and preparation method thereof | |
| CN101264215A (en) | Medicinal composition for treating acute and chronic urarthritis and preparation thereof | |
| CN100457143C (en) | Medication for treating gout | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN104258051B (en) | Traditional Chinese medicine composition for treating gouty arthritis, and preparation method thereof | |
| CN105267559A (en) | Diabetic peripheral neuropathy treatment medicine and manufacturing method thereof | |
| CN101919985A (en) | Drug for treating fatty liver and preparation method and use thereof | |
| CN104645015A (en) | Traditional Chinese medicine compound preparation for treating vascular dementia and preparation method of traditional Chinese medicine compound preparation | |
| CN100402065C (en) | Capsule for treating gout and preparation process thereof | |
| CN1264536C (en) | Anti-gout composition and preparing process thereof | |
| CN1562274A (en) | Preparation of pure Chinese traditional medicine for curing acute nephritis and chronic nephritis | |
| CN100333758C (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN1215876C (en) | Antigout medicinal composition and its preparing method | |
| CN104887968A (en) | Traditional Chinese medicine preparation for preventing contrast associated nephropathy as well as preparation method | |
| CN103599419B (en) | Traditional Chinese medicine combination for treating gout | |
| CN103127358B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method | |
| CN1235605C (en) | Medicinal composition for treating gall | |
| CN104435149A (en) | Traditional Chinese medicine composition containing kadsura pepper stem for treating gout | |
| CN101590208A (en) | A kind of pharmaceutical composition for the treatment of rheumatoid arthritis and preparation method thereof | |
| CN107303330A (en) | One kind prevents antipodagric Chinese medicine composition and preparation method and application | |
| CN106177250A (en) | A kind of Chinese medicine composition treating chronic nephritis | |
| CN104800637A (en) | Traditional Chinese medicine composition for treating hyperuricemia with joint swelling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: CHENGDU HUAXI NATURAL MEDICINES CO., LTD. Free format text: FORMER OWNER: ZHONGHUI PHARMACY CO., LTD., CHENGDU Effective date: 20080627 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080627 Address after: Sichuan city of Chengdu province Guo Jia Qiao No. 5 North Street Post encoding: 610016 Applicant after: Chengdu Huaxi Natural Pharmacy Co., Ltd. Address before: 30, Shu West Road, Chengdu, Sichuan Province, China: 610036 Applicant before: Zhonghui Pharmaceutical Co., Ltd., Chengdu City |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090204 Termination date: 20191129 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| RR01 | Reinstatement of patent right | ||
| RR01 | Reinstatement of patent right |
Former decision: Termination of patent right without paying annual fee Former decision publication date: 20201106 |